Article
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2008
Fidler Mary J, Argiris Athanassios, Patel Jyoti D, Johnson David H, Sandler Alan, Villaflor Victoria M, Coon John, Buckingham Lela, Kaiser Kelly, Basu Sanjib, Bonomi Philip
Abstract excerpt
PURPOSE: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non-small cell lung cancer (NSCLC). With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC. EXPERIMENTAL DESIGN: Previously treated stage IIIB/IV NSCLC patients were given...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.